Calculator for ovarian carcinoma subtype prediction (Q33763357)

29 July 2017

title

Calculator for ovarian carcinoma subtype prediction (English)

1 reference

29 July 2017

1 reference

C Blake Gilks

1 reference

29 July 2017

Steve E Kalloger

1 reference

29 July 2017

Martin Köbel

1 reference

29 July 2017

Samuel Leung

1 reference

29 July 2017

Erika Mehl

1 reference

29 July 2017

Dongxia Gao

1 reference

29 July 2017

Krista M Marcon

1 reference

29 July 2017

Christine Chow

1 reference

29 July 2017

Blaise A Clarke

1 reference

29 July 2017

David G Huntsman

1 reference

29 July 2017

publication date

3 December 2010

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

1 reference

29 July 2017

page(s)

512-521

1 reference

29 July 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Differences in tumor type in low-stage versus high-stage ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Ovarian carcinoma pathology and genetics: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Mammaglobin B expression in human endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Mutation ofFOXL2in Granulosa-Cell Tumors of the Ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immuno

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

The heterogeneity of epithelial ovarian cancer: getting it right

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

7 January 2021

Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

7 January 2021

Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

7 January 2021

CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

7 January 2021

IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

7 January 2021

p16INK4a Immunohistochemistry Improves Interobserver Agreement in the Diagnosis of Cervical Intraepithelial Neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.215

7 January 2021

10.1038/MODPATHOL.2010.215

Identifiers

DOI

1 reference

Dimensions Publication ID

29 July 2017

1010693560

0 references

1 reference